Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
12 citations
,
January 2003 in “Dermatology Online Journal” A new treatment for hair loss was tested and most participants saw their hair loss stop within 2-8 weeks, with up to 50% more hair after 4 months, and no side effects.
Antifungal treatment reduced asthma exacerbations and corticosteroid use but its overall benefit is unclear.
CG2001 is safe and well-tolerated for treating hair loss in men.
8 citations
,
February 2025 in “Swiss Medical Weekly” Integrating best practices for steroid users in Swiss primary care is feasible and beneficial, but doping laws need change.
August 2021 in “The Journal of Urology” Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.
38 citations
,
January 2013 in “Dermatology” Careful patient selection is key for effective pulse corticosteroid treatment in children with alopecia areata.
January 2021 in “Journal of the European Academy of Dermatology and Venereology” PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.
1 citations
,
May 2002 in “The Journal of Urology”
136 citations
,
April 2016 in “Dermatologic Surgery” PRP treatment helps hair growth and density in androgenetic alopecia patients.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
June 2026 in “Value in Health”
January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.
January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
1 citations
,
December 2025 in “Journal of the American Academy of Dermatology” 2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
9 citations
,
December 2009 in “Cancer Research” Both vaginal testosterone cream and Estring effectively manage vaginal dryness in women with early-stage breast cancer on aromatase inhibitors.
September 2023 in “Journal of the American Academy of Dermatology” 3 citations
,
April 2020 in “Medicine” Acupuncture may be a safe and cost-effective treatment for Seborrheic alopecia.
5 citations
,
December 2018 in “The Journal of clinical psychiatry/The journal of clinical psychiatry” Tamsulosin may slightly increase dementia risk compared to other treatments for enlarged prostate.
October 2025 in “International Journal of Clinical Trials” India is ideal for dermatology trials due to diverse patients and cost-effectiveness.
5 citations
,
July 2019 in “Applied statistics/Journal of the Royal Statistical Society. Series C, Applied statistics” Case-only trees and random forests improve predictions of treatment effects in clinical trials.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
October 2019 in “Research Square (Research Square)” YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
1 citations
,
April 1953 in “Acta Radiologica” Irradiating the whole central nervous system can lead to over 50% of patients with cerebellar medulloblastoma surviving three years.
May 2026 in “British Journal of Clinical Pharmacology” Hair analysis has potential but is currently limited for monitoring medication adherence.
August 2023 in “Journal of Cosmetic Dermatology” Higher concentration of botulinum toxin A is safe and effective for treating hair loss in men and women.
35 citations
,
March 2010 in “Journal of Dermatological Science” Ebastine may help regrow hair in alopecia areata patients.
November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
4 citations
,
October 2020 in “Research Square (Research Square)” Early treatment with certain drug combinations improved COVID-19 outcomes and prevented severe disease in males, including those at higher risk.